Skip to main content
The Egyptian Journal of Bronchology
Download PDF

Short-term evaluation of motor and sensory nerve conduction parameters in COVID-19-associated peripheral neuropathy patients

The Egyptian Journal of Bronchology volume 17, Article number: 15 (2023) Cite this article

A Letters to the Editor to this article was published on 10 May 2023

Abstract

Background

Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) is mostly associated with upper and lower respiratory tract manifestations. However, coronavirus disease 19 (COVID-19) can result in a wide range of other systemic symptomatology, including neuropsychiatric, psychological, and psychosocial impairments. Literature regarding neurological compromise, including neuropathy and sensory and motor affection associated with COVID-19, is still limited.

This study aims to evaluate the sensory, motor neuropathy, and secondary neurological impairment among patients with mild to moderate coronavirus disease associated with peripheral neuropathy within 1 month.

Methods

Forty participants, including 20 mild to moderate COVID-19 patients with peripheral neuropathy and 20 age and gender-matched healthy volunteers, were recruited in this case/control study. Laboratory evaluation focused on C-reactive protein (CRP) and D-dimer levels. Oxygen saturation for all participants was recorded. The neurophysiological study included motor nerve study, sensory nerve study, and F wave study for upper and lower limbs were done.

Results

The two groups were similar regarding baseline data. Neurological symptoms’ onset in the COVID-19 group ranged from 4 to 24 days. Levels of CRP and D-dimer levels were significantly higher in patients versus the control group. Motor nerve conduction (MNC) amplitude and latency for the median nerve were significantly compromised among the COVID-19 group. The MNC latency and F wave latency for the posterior tibial nerve were significantly higher in the COVID-19 group. The CRP and D-dimer levels were associated with a significant positive correlation with a latency of median nerve MNC, sensory nerve conduction (SNC), and f-wave; latency of MNC and F wave of the posterior tibial nerve; and SNC latency for sural nerve.

Conclusion

neurological involvement can occur in mild to moderate cases of SARS-COV-2 infection and add to the burden of the disease. Neurological symptoms in the course of COVID-19 disease should be interpreted cautiously, and appropriate diagnosis, including nerve conduction studies and management, should be considered.

Trial registration

ClinicalTrials.gov. NCT05721040.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first emerged in Wuhan, China, can result in a wide variety of symptomatology ranging from asymptomatic infection up to pneumonia, respiratory failure, or even death [1].

Respiratory involvement is the prevalent form of COVID-19 disease; however, growing evidence suggests neurological manifestations to be a direct consequence and even the presenting manifestation in a large proportion of patients [2]. Cerebrovascular diseases, including stroke, encephalitis, neuropathy, visual pathway abnormality, and Guillain-Barré syndrome, were recorded. Other common features encountered early in the course of infection were loss of smell (anosmia) and taste (ageusia) [3,4,6].

Several theories emerged to explain neurological manifestations, including direct neuroinvasion by the coronavirus, [7, 8] explained through the activation of the angiotensin-converting enzyme 2 (ACE-2) receptor expressed in both capillary and neuronal endothelium [9]. Dysregulated immune response, [10, 11] hypoxemia, multiorgan involvement, and increased prothrombin time and coagulopathy are other explanations [12, 13].

This study aims to evaluate the pattern of motor and sensory, and neurological affections in mild to moderate COVID-19 with associated peripheral neuropathy patients and explore the relationship between inflammatory status and neurological deficits.

Patients and methods

Study design and participants

This prospective case–control study was conducted in the Chest Department, Faculty of Medicine, Assiut University, and the Neurology Department, Faculty of Medicine, Assiut University, between October 2021 and April 2022. Twenty RT-PCR-confirmed mild to moderate COVID-19 patients with peripheral neuropathy presented within 1 month of acute disease at outpatient clinics of the Chest and Neurology Departments were recruited and twenty healthy age and gender-matched volunteers.

Inclusion and exclusion criteria

All patients with confirmed RT-PCR COVID-19 infection with mild to moderate severity based on the Egyptian Ministry of Health (MOH) protocol (version 1.4, November 2020) with neurological symptoms suggestive of peripheral neuropathy were eligible for participation in the current study. Exclusion criteria were patients presenting with neurological manifestations other than peripheral neuropathy, such as stroke, cerebral hemorrhage, encephalitis, or meningitis. Patients with any medical condition or comorbidities that may affect the result of the study as diabetes, arthritis, and carpel tunnel syndrome were excluded. Severe COVID-19 patients with a critical condition that needs hospitalization and ventilatory support were also excluded from the study.

Clinical and laboratory assessment

All patients were subjected to intense history taking, including the onset of the COVID-19 infection and the start of neurological symptoms, careful clinical examination, and neurological assessment. All patients and control groups had oxygen saturation, CPR, and D-dimer measurement at the time of the study.

Neurophysiological study

All studies were conducted using A Nihon Kohden Machine model 9400 (Tokyo, Japan).

The motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs. A standard procedure with concentric needle electrodes is used to assess motor nerve conduction velocity. Supramaximal intensity stimulation with a duration of 0.2 ms with a rate of one per second was performed. Compound motor action potential (CMAP), motor nerve conduction velocity (MNCV), and nerve conduction latency were recorded.

The sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs. The analysis was performed using stimulating ring electrodes placed over the middle and proximal phalanxes of the second and third fingers. In contrast, the recording electrode is placed over the palm in a position 1–2 cm proximal to the proximal crease of the palm. The sensory nerve conduction study of the sural nerve was performed by placing surface recording electrodes over the posterior aspect of the calf at a point between the middle and lower thirds of the leg, just lateral of the midline. Stimulating electrodes are placed behind and below the lateral malleolus over the sural nerve. Sensory motor nerve conduction amplitude, latency, and velocity were recorded.

F wave study was performed for the upper limb in the median nerve by placing the recording electrode at the abductor pollices brevis muscle. In contrast, the recording electrodes were placed two cm distal near the tendon insertion. For testing the F wave in the posterior tibial nerve for the lower limb, recording electrodes were placed over the abductor hullucis muscle, and the stimulating electrodes were placed at the malleolus. For F wave recording, a supramaximal stimulus was performed, ten stimuli were given, and their average was recorded.

For all parameters of neurophysiological studies, the values below the 95th percentile or ± 2SD of control are considered abnormal. Diffuse axonal neuropathy was diagnosed by the reduction of CMAP amplitude with standard shape and duration and with normal or minimal disturbance of nerve conduction velocity. In contrast, diffuse demyelinating neuropathy was diagnosed by increased nerve conduction latency, preserved amplitude, and average nerve conduction velocity.

Statistical analysis and sample size were performed using the SPSS program (version 20, IBM and Armonk, New York). The Mann–Whitney test was used for continuous data, while chi2 test compared nominal data. Different correlations of continuous variables in the study were assessed with Spearman’s correlation. The sample size was estimated by Open Epi V.3.01 computer program.

Ethical considerations

All participants subjected to the study were asked to apply informed written consent; the research’s nature, procedures, and possible side effects were clearly explained. The Faculty of Medicine, Assiut University’s ethical committee approved the study protocol under the Declaration of Helsinki.

Results

In the current study, we recruited twenty COVID-19 patients with confirmed diagnoses by RT-PCR with neurological symptoms and twenty genders and age-matched healthy volunteers.

The demographic characteristics of the patients and the control group are shown in (Table 1). There was no significant difference between the two groups regarding age, gender, education, smoking, and residence. The mean onset of neurological symptoms is 11.95 ± 5.9 days and ranges from 4 to 24 days.

Table 1 Demographic data of the COVID-19 patients with peripheral neuropathy and control group (n = 40)
Full size table

There were significant differences between the patient group and the control group regarding; CRP level, where the mean value in the COVID-19 group was 39.7 ± 7.46 and 6.3 ± 2.15 in the control group with a p value of < 0.001, D-dimer with a mean value in the patients’ group of 983.6 ± 324.88 and the control group of 315.3 ± 63.03 with a p value of < 0.001 and oxygen saturation in the COVID-19 group with the mean of 96.95 ± 1.35 and the control group of 98.5 ± 0.61 with a p value of 0.009 (Table 2).

Table 2 Laboratory data and oxygen saturation level of the COVID-19 patients with peripheral neuropathy and control group (n = 40)
Full size table

Regarding the nerve conduction study in both groups, there was a significant difference between the two groups in median nerve motor nerve conduction amplitude (MNCA) with a mean of 8.88 ± 2.6 and 9.04 ± 2.12 in the control group with a P value of 0.039. There was a significant statistical difference between the two groups in median nerve motor nerve conduction latency (MNCL) with a mean of 5.1 ± 1.34 and 3.29 ± 0.64 in the control group with a P value of < 0.001. There was a significant statistical difference between the two groups in posterior tibial nerve motor nerve conduction latency (MNCL) with a mean of 3.99 ± 0.99 and 3.06 ± 0.61 in the control group with a P value of 0.007. There was a significant statistical difference between the two groups in Posterior tibial nerve F wave latency with a mean of 52.28 ± 4.95 and 47.25 ± 3.17 in the control group with a P value of 0.002 (Table 3).

Table 3 Electrophysiological measurements of the COVID-19 group with the peripheral neuropathy and control group (n = 40)
Full size table

We correlated the laboratory data and age with the neurophysiological parameters. There was a positive correlation between CRP level and median nerve (MNCL) with r = 0.787, p value < 0.001; median nerve (SNCL) with r = 0.668, p value < 0.001; median nerve F wave latency with r = 0.386, p value < 0.014; posterior tibial nerve (MNCL) with r = 0.611, p value < 0.001; sural nerve (SNCL) with r = 0.624, p value < 0.001; and posterior tibial nerve F wave latency with r = 0.544, p value < 0.001.

There was a positive correlation between D-dimer level and median nerve (MNCL) with r = 0.702, p value < 0.001; median nerve (SNCL) with r = 0.590, p value < 0.001; median nerve F wave latency with r = 0.418, p value < 0.007; posterior tibial nerve (MNCL) with r = 0.493, p value < 0.001; sural nerve (SNCL) with r = 0.657, p value < 0.001; and posterior tibial nerve F wave latency with r = 0.557, p value < 0.001.

There was a negative correlation between oxygen saturation and median nerve (SNCL) with r =  − 0.542, p value < 0.001; median nerve F wave latency with r =  − 0.364, p value < 0.021; posterior tibial nerve (MNCL) with r =  − 0.565, p value < 0.001; sural nerve (SNCL) with r =  − 0.640, p value < 0.001; posterior tibial nerve F wave latency with r =  − 0.546, p value < 0.004; and positive correlation between oxygen saturation and median nerve (MNCL) with r = 0.619, p value < 0.001; median nerve (SNCV) with r = 0.328, p value 0.039; and posterior tibial nerve (CMAP) with r = 0.312, p value 0.049) (Table 4).

Table 4 Correlation of age, CRP value, D-dimer value, and SpO2 with nerve conduction study results in COVID-19 cases with peripheral neuropathy (n = 20)
Full size table

Stratification of the motor nerve conduction study of the COVID-19 group revealed that 10% of patients had motor axonal neuropathy, 15% mixed motor neuropathy, and 55% demyelinating motor neuropathy, while 20% of patients with a normal study (Fig. 1). Assessment of the sensory nerve conduction study showed that 5% of patients had sensory axonal neuropathy, 15% mixed sensory neuropathy, and 45% sensory demyelinating neuropathy, while 35% of patients with a normal study (Fig. 2).

Fig. 1
figure 1

Frequency and types of motor neuropathies among COVID-19 groups (n = 20)

Full size image
Fig. 2
figure 2

Frequency and types of sensory neuropathies among COVID-19 groups (n = 20)

Full size image

Discussion

In the current study, we enrolled twenty mild to moderate COVID-19 patients with peripheral neuropathy and compared them with 20 age and sex-matched healthy controls. Neurophysiological studies revealed a significant difference between the two groups in compound motor action potential and motor nerve conduction latency of the median nerve and motor nerve conduction latency of the posterior tibial nerve and F wave latency of the posterior tibial nerve. There was a positive correlation between oxygen saturation and SNC velocity of the median nerve, the MNC amplitude of the post-tibial nerve. There was a strong negative correlation between SpO2 and MNC latency, SNC latency, and F wave latency of the median nerve. Also, strong negative correlation between SpO2 and MNC latency of the posterior tibial nerve, SNC latency of the sural nerve, and F wave latency of the posterior tibial nerve.

There was a strong positive correlation between D-dimer level and CRP level with MNC, SNC, and F wave latencies of the median nerve, MNC and F wave latencies of the posterior tibial nerve, and SNC latency of the sural nerve. Motor axonal neuropathy was observed in 10% of patients; motor demyelinating neuropathy was observed in 55%, and mixed motor neuropathy in 15%. Sensory axonal neuropathy was observed in 5% of patients; demyelinating sensory neuropathy was observed in 45%, and mixed sensory neuropathy in 15%.

Neurological affection is observed throughout the course of the COVID-19 infection. A study by Mao and his colleagues on 214 COVID-19 patients observed the presence of neurological manifestations in 36% of the study group [14]. Although SAR-COV-2 is not documented to be present in CSF of affected patients during the course of COVID-19 infection; there is a strong association between the presence of neurological symptoms and SARS-COV-2 infection [15].

In an attempt to explain the pathophysiology of neurological affection in SARS-COV-2 infection; the international human cell atlas community has reported increased expression of two key co-receptors during SARS-COV-2 infection, namely ACE2 and TMPRSS2 co-receptors [16]. Another theory is the para-infectious neurological syndrome due to SARS-COV-2 infection [17].

A possible etiological explanation is the host immune response to SARS-COV-2 and the development of cytokine storms [18]. Peripheral nervous system and muscle affection is common through the course of SARS-COV-2 infection with a median of 7 days (range 7–24) [19].

In agreement with our study, EL-Leithy et al. enrolled 60 COVID-19 patients in 3 groups (20 mild, 20 moderate, and 20 severe cases) with a significant difference in upper and lower nerve conduction study between the patient groups and the control group, which were significantly correlated to the CRP level [20].

Elshebawy et al. enrolled 42 patients; 23 of them were in the first wave of COVID-19, and 19 were in the second wave; the characteristics of the study groups showed the presence of acute inflammatory demyelinating neuropathy in 47.8% of the 1st wave patients, and 73.7 in the 2nd wave patients and the demyelinating with secondary axonal affection in 13% of the 1st wave patients and 10.5% of 2nd wave patients [21].

Ellul and colleagues using data available up to May 19, 2020. COVID-19 cases based on Johns Hopkins COVID-19 Dashboard demonstrated that peripheral neuropathy is present in 0.05% of COVID-19 patients [16].

In a Cohort of Egyptian Patients with COVID-19, Mekkawy and colleagues described peripheral nervous manifestations in 29.04% of patients early from the 1st day to 7 days of infection and late from the 8th to the 15th day of affection. Muscle injury was present in 1.37% of patients, and symmetrical lower limb distal sensory neuropathy in 1.55% of the patients [22].

Bagnato and colleagues evaluated 21 patients after COVID-19 infection; neuromuscular affection was demonstrated in 17 patients. Affection varied between critical illness myopathy (CIM), critical illness polyneuropathy (CIP), Guillain-Barré syndrome, and peroneal nerve injury [23].

Conclusion

Neurological affection including peripheral neuropathy associated with SARS-COV-2 should not be overlooked. Affected personnel may be limited in number but during a massive pandemic, this can have a tremendous effect. Careful short-term neurological assessment is needed for symptomatic patients and can result in early detection and appropriate management.

Limitations

Long-term follow-up can be done in the future to identify the long-term neurological effects of SARS-COV-2.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

ACE-2:

Angiotensin-converting enzyme 2

COVID-19:

Coronavirus disease 2019

CRP:

C-reactive protein

CMAP:

Compound motor action potential

EMG:

Electromyography

MOH:

Ministry of Health

MNC:

Motor nerve conduction

MNCA:

Motor nerve conduction amplitude

MNCL:

Motor nerve conduction latency

MNCV:

Motor nerve conduction velocity

RT-PCR:

Reverse transcription-polymerase chain reaction

SARS‐COV‐2:

Severe acute respiratory syndrome coronavirus 2

SNC:

Sensory nerve conduction

SNCA:

Sensory nerve conduction amplitude

SNCL:

Sensory nerve conduction latency

SNCV:

Sensory nerve conduction velocity

SPO2 :

Saturation of peripheral oxygen

SPSS:

Statistical Package for Social Sciences

References

  1. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, Smith L (2020) Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health 17(8):2690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 395(10223):507–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M et al (2019) Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system. Viruses 12(1):14

    Article  PubMed  PubMed Central  Google Scholar 

  4. Andalib S, Biller J, Di Napoli M, Moghimi N, McCullough LD, Rubinos CA, O’HanaNobleza C, Azarpazhooh MR, Catanese L, Elicer I, Jafari M (2021) Peripheral nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep 21:1–4

    Article  Google Scholar 

  5. Koskderelioglu A, Eskut N, Ortan P, Ozdemir HO, Tosun S (2022) Visual evoked potential and nerve conduction study findings in patients recovered from COVID-19. Neurol Sci 1:1–9

    Google Scholar 

  6. Lüers JC, Klußmann JP, Guntinas-Lichius O (2020) COVID-19-pandemie und das HNO-Fachgebiet: Worauf kommt es aktuell an? (The COVID-19 pandemic and otolaryngology: what it comes down to?). Laryngorhinootologie 99(5):287–91

    Article  PubMed  Google Scholar 

  7. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ (2014) Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res 19(194):145–158

    Article  Google Scholar 

  8. Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A (2020) Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol 27(9):1764–1773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Toljan K (2020) Letter to the editor regarding the viewpoint “evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanism.” ACS Chem Neurosci. 11(8):1192–4

    Article  CAS  PubMed  Google Scholar 

  11. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y (2020) Desregulación de la respuesta inmune en pacientes con coronavirus 2019 (COVID-19) en Wuhan, China. Enferm Infecc Infecc Clín 71(15):762–768

    CAS  Google Scholar 

  12. Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely E (2020) COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care 24(1):1–9

    Article  Google Scholar 

  13. Wang HY, Li XL, Yan ZR, Sun XP, Han J, Zhang BW (2020) Potential neurological symptoms of COVID-19. Ther Adv Neurol Disord 13:1756286420917830

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Li Y, Jin H, Hu B (2020) Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. MedRxiv 25:2020–2102

    Google Scholar 

  15. Filatov A, Sharma P, Hindi F, Espinosa PS (2020) Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus 12(3):e7352

    PubMed  PubMed Central  Google Scholar 

  16. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet Neurol 19(9):767–83

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ftiha F, Shalom M, Jradeh H (2020) Neurological symptoms due to coronavirus disease 2019. Neurol Int 12(1):8639

    Article  PubMed  PubMed Central  Google Scholar 

  19. Abdelnour L, EltahirAbdalla M, Babiker S (2020) COVID-19 infection presenting as motor peripheral neuropathy. J Formos Med Assoc 119:1119–1120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. El-Leithy SA, Mohamed HA, El-Bably MM (2021) Nerve conduction studies in post-COVID-19 patients among Egyptian patients. Int J Curr Res Rev. https://doi.org/10.31782/IJCRR.2021.131245

    Article  Google Scholar 

  21. Elshebawy H, Ezzeldin MY, Elzamarany EH (2021) Characteristics of COVID and post-COVID polyneuropathies in adults and pediatrics: an Egyptian sample. Egypt J Neurol Psychiatry Neurosurg 57:1–7

    Article  Google Scholar 

  22. Mekkawy DA, Hamdy S, Abdel-Naseer M, Shehata HS, Halfawy AA, Shalaby NM, Shehata GA, Ali AM, Elmazny A, Ahmed SM, Ismail JH (2022) Neurological manifestations in a cohort of Egyptian patients with COVID-19: a prospective, multicenter, observational study. Brain Sci 12(1):74

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bagnato S, Ferraro M, Boccagni C, Battaglia G, D’Agostino T, Prestandrea C, Bellavia MA, Rubino F (2021) COVID-19 neuromuscular involvement in post-acute rehabilitation. Brain Sci 11(12):1611

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Chest Department, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt

    Ahmad M. Shaddad, Aliaë A. R. Mohammed Hussein & Waleed Gamal Elddine Khalil

  2. Neuropsychiatry Department, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt

    Amal Mohamed Aly Tohamy

Authors
  1. Ahmad M. Shaddad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aliaë A. R. Mohammed Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Mohamed Aly Tohamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Waleed Gamal Elddine Khalil
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AMS, AARMH, AMAT, and WGEK: conception and design. AMS, AMAT, and WGEK: data collection. AMS and WGEK: statistical analysis. AMS, AARMH, AMAT, and WGEK: medical writing. The authors revised the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Ahmad M. Shaddad.

Ethics declarations

Ethics approval and consent to participate:

The study was approved by the institutional review board and ethical committee of the Faculty of Medicine—Assiut University in compliance with the Helsinki declaration (IRB: 04–2023-300077).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shaddad, A.M., Hussein, A.A.R.M., Tohamy, A.M.A. et al. Short-term evaluation of motor and sensory nerve conduction parameters in COVID-19-associated peripheral neuropathy patients. Egypt J Bronchol 17, 15 (2023). https://doi.org/10.1186/s43168-023-00189-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43168-023-00189-3

Keywords